MedTrace Logo

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

NCT03019419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-01-15

No results posted yet for this study

Summary

To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis

Conditions

Interventions

DRUG

Perampanel

4mg/d or 8mg/d

DRUG

placebo

placebo

Sponsors & Collaborators

  • Tokyo Medical University

    lead OTHER

Principal Investigators

  • Tomohiro Haga · The University of Tokyo Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2020-12-23
Completion
2020-12-23

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019419 on ClinicalTrials.gov